Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07236203Recruiting
Study of CAR-T therapy for relapsed large B-cell lymphoma
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT07634653Recruiting
Strength Training for Kids with Newly Diagnosed Blood Cancer
This study tests whether strength training exercises during cancer treatment can help children with acute lymphoblastic leukemia or lymphoblastic lymphoma feel stronger and recover better. The research includes optional interviews with parents to understand how the program affects families.
Chapel Hill, North CarolinaAges 6 years+ - NCT07029737RecruitingPhase 2
Studying acalabrutinib with R-CHOP for untreated mantle cell lymphoma
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
A CoruñaAges 18–130 - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT01676805Recruiting
Collecting tissue samples for lymphoma research
This study collects leftover tissue samples from patients with or without lymphoma to help researchers better understand lymph system cancers. It may be an option if you are already having a biopsy or surgery.
Bethesda, MarylandAges 18 years+ - NCT05705531Recruiting
Cardiac MRI study of heart health after Hodgkin lymphoma treatment
This study looks at how certain blood-related “growth patterns” connect to long-term heart health after treatment for classical Hodgkin lymphoma. It may help doctors better predict who could develop heart problems and how to monitor them over time.
Mobile, AlabamaAges 7 years+ - NCT06785818Recruiting
Long-term follow-up of Kymriah patients in South Korea
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
Bundang Gu, Gyeonggi-doAges birth–100 years - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Tucson, ArizonaAges 18 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Huntington Park, CaliforniaAges 18 years+ - NCT04840602RecruitingPhase 2
Venetoclax plus rituximab versus standard Waldenstrom treatment
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Tucson, ArizonaAges 18 years+ - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT07727642Recruiting
Optimizing HIV Medicines for AIDS-Related Lymphoma
This trial helps doctors find the best way to combine HIV medicines (antiretroviral therapy) with lymphoma treatment for people who have both HIV and AIDS-related lymphoma. The goal is to improve your overall care and outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07654426RecruitingPhase 2
Heart protection during lymphoma chemotherapy
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
Boston, MassachusettsAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT06445517RecruitingPhase 1
ISM8207 for advanced solid tumors and B-cell lymphoma
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07082686RecruitingPhase 2
A study of ICP-248 for mantle cell lymphoma that has come back or not responded
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
Hefei, AnhuiAges 18 years+ - NCT07719556RecruitingPhase 2
Orelabrutinib with obinutuzumab and venetoclax for untreated MCL
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Changzhou, JiangsuAges 18 years+ - NCT06863402RecruitingPhase 2
Study of two drugs for Richter transformation lymphoma
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Buffalo, New YorkAges 18 years+ - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06533748RecruitingPhase 2
New treatment for kids with B-cell leukemia or lymphoma
This trial tests a new therapy plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma. It aims to improve outcomes for those with higher-risk features.
Charlotte, North CarolinaAges 1–18 - NCT06390319RecruitingPhase 2
Adding dasatinib or venetoclax for children with T-cell leukemia or lymphoma
This trial tests whether adding either dasatinib or venetoclax to standard chemotherapy can improve outcomes for children aged 1 to 18 with newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. It compares the effects of these added drugs to help doctors find better treatment options.
San Diego, CaliforniaAges 1–18 - NCT02964858Recruiting
Testing the best radiation dose after R-CHOP for lymphoma
This trial studies how to choose the safest and most effective radiation dose for diffuse large B-cell lymphoma (a type of non-Hodgkin lymphoma) after standard chemotherapy. It may help improve disease control while aiming to limit side effects from radiation.
Mumbai, MaharashtraAges 18–65
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,373 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.